United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

valneva uk ltd - vibrio cholerae - oral suspension

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - vibrio cholerae, quantity: 31.25 billion organisms; vibrio cholerae, quantity: 1 mg - oral liquid, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate dihydrate; water for injections; monobasic sodium phosphate dihydrate - cholera caused by serogroup 01 vibrio cholerae: active immunisation of adults and children from two years of age, who will be visiting areas epidemic or endemic for cholera and who are at high risk of infection.

European Union - English - EMA (European Medicines Agency)

valneva sweden ab - recombinant cholera toxin b subunit, vibrio cholerae 01 - cholera; immunization - vaccines - dukoral is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas.the use of dukoral should be determined on the basis of official recommendations taking into consideration the variability of epidemiology and the risk of contracting disease in different geographical areas and travelling conditions.dukoral should not replace standard protective measures. in the event of diarrhoea measures of rehydration should be instituted.

European Union - English - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, strain cvd 103-hgr, live - cholera - vaccines - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older.this vaccine should be used in accordance with official recommendations.

Philippines - English - FDA (Food And Drug Administration)

medical vaccines online deliveries; distributor: medical vaccines online deliveries - cholera vaccine (inactivated, oral) - oral suspension - formulation each dose (1.5 ml), contains vibrio cholerae 01 inaba cairo 48 classical biotype, heat inactivated vibrio cholerae 01 inaba phil 6973 el tor biotype, formalin inactivated vibrio cholerae 01 ogawa cairo 50 classical biotype, formalin inactivated vibrio cholerae 01 ogawa cairo 50 classical biotype, heat inactivated vibrio cholerae 0139 4260b, formalin inactivated 300 leu* 600 leu* 300 leu* 300 leu* 600 leu* *leu: lipopolysaccharide elisa units

Singapore - English - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - recombinant cholera toxin b subunit (rctb); vibrio cholerae o1 inaba classic strain (heat inactivated); vibrio cholerae o1 inaba el tor strain (formalin inactivated); vibrio cholerae o1 ogawa classic strain (formalin inactivated); vibrio cholerae o1 ogawa classic strain (heat inactivated) - suspension - 1 mg/dose - recombinant cholera toxin b subunit (rctb) 1 mg/dose; vibrio cholerae o1 inaba classic strain (heat inactivated) 31.25 x 10^9 bacteria; vibrio cholerae o1 inaba el tor strain (formalin inactivated) 31.25 x 10^9 bacteria; vibrio cholerae o1 ogawa classic strain (formalin inactivated) 31.25 x 10^9 bacteria; vibrio cholerae o1 ogawa classic strain (heat inactivated) 31.25 x 10^9 bacteria

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - recombinant cholera toxin b subunit 1mg; vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated); vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated); vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) - oral suspension - active: recombinant cholera toxin b subunit 1mg vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated) vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated) vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate dihydrate citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate - active immunisation of adults and children from two years of age, who will be visiting areas with an ongoing or anticipated epidemic or who will be spending an extended period of time in areas in which cholera infection is a risk. the vaccine should be considered for foreign aid workers and others intending to visit or spend an extended period of time in areas endemic or epidemic for cholera.

Canada - English - Health Canada

valneva sweden ab - vibrio cholerae ogawa 50 classical biotype, formalin inactivated; recombinant cholera toxin b subunit; vibrio cholerae inaba 6973 el tor biotype, formalin inactivated; vibrio cholerae inaba 48 classical biotype, heat inactivated; vibrio cholerae ogawa 50 classical biotype, heat inactivated - suspension - 31250000000cells; 1mg; 31250000000cells; 31250000000cells; 31250000000cells - vibrio cholerae ogawa 50 classical biotype, formalin inactivated 31250000000cells; recombinant cholera toxin b subunit 1mg; vibrio cholerae inaba 6973 el tor biotype, formalin inactivated 31250000000cells; vibrio cholerae inaba 48 classical biotype, heat inactivated 31250000000cells; vibrio cholerae ogawa 50 classical biotype, heat inactivated 31250000000cells - vaccines

United States - English - NLM (National Library of Medicine)

paxvax, inc. - vibrio cholerae cvd 103-hgr strain live antigen (unii: v9g528e9e0) (vibrio cholerae cvd 103-hgr strain live antigen - unii:v9g528e9e0) - vibrio cholerae cvd 103-hgr strain live antigen 1200000000 [cfu] - vaxchora is a vaccine indicated for active immunization against disease caused by vibrio cholerae serogroup o1 in adults 18 through 64 years of age traveling to cholera-affected areas. the effectiveness of vaxchora has not been established in persons living in cholera-affected areas. the effectiveness of vaxchora has not been established in persons who have pre-existing immunity due to previous exposure to v. cholerae or receipt of a cholera vaccine. vaxchora has not been shown to protect against disease caused by v. cholerae serogroup o139 or other non-o1 serogroups. do not use in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of vaxchora or to a previous dose of any cholera vaccine [see description (11)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to vaxchora during pregnancy. to enroll in or obtain information about the registry, please call paxvax at 1-800-533-5899. risk summary vaxch

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - vibrio cholerae -